𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Fecal α1-antitrypsin: A marker of intestinal versus systemic inflammation in pediatric Crohn's disease?

✍ Scribed by D. Herzog; E. Delvin; Dr. E. Seidman

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
640 KB
Volume
2
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

✦ Synopsis

Growth failure and malnutrition are major concerns in pediatric patients with frequent relapses of Crohn's disease (CD). In search of an early, noninvasive marker of relapse, we prospectively examined the relationship between levels of fecal al-antitrypsin (ctl-AT) in comparison with other known inflammatory parameters and disease activity using a pediatric CD Activity Index (P-CDAI), as well as in relation to growth. Forty-two pediatric patients (29 M, 13 F, 7-16 years old, mean 12.8 years) with ileal or ileocolonic CD were prospectively examined at 4 monthly intervals over a 1 year period. Medmn (interquartile range) fecal ctl-AT values did not differ between

📜 SIMILAR VOLUMES

Fecal α1-antitrypsin (α1-AT): A marker o
Fecal α1-antitrypsin (α1-AT): A marker of inflammation in pediatric Crohn's disease (CD)
✍ D. Herzog; E. Seidman; E. Delvin 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 133 KB

In a cohort study, the blood lipids of 35 children aged 6-8, 20 boys and 15 girls, and their parents were estimated to assess their relationship to energy expenditure measured using a minute-by-minute heart-rate method. Blood cholesterol and triglycerides were estimated using a Reflolron (Boehringer

Serum α1-antitrypsin levels as a marker
Serum α1-antitrypsin levels as a marker of activity in pediatric inflammatory bowel disease
✍ Dr. Michael J. Pettei; Jeremiah J. Levine 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB

The purpose of this study was to evaluate the use of the acute-phase serum protein a,-antitrypsin (a,- AT) compared with the erythrocyte sedimentation rate (ESR), platelet count, and hemoglobin level in screening for inflammation in newly diagnosed and known patients with inflammatory bowel disease